TMCnet News
CSA Medical Supports Esophageal Cancer Awareness MonthLEXINGTON, Mass., April 2, 2018 /PRNewswire/ -- April is Esophageal Cancer Awareness month. CSA Medical is committed to raising awareness of Esophageal Cancer and the importance of early diagnosis and treatment. CSA Medical supports the efforts of the Esophageal Cancer Action Network's (ECAN) mission to save lives by increasing awareness of the link between heartburn and cancer, promoting early detection and treatment, and supporting medical innovation to prevent, detect, treat and cure Esophageal Cancer. To learn more about esophageal cancer, visit www.ecan.org CSA Medical's truFreeze® Spray Cryotherapy System is the only minimally invasive ablation methodology with FDA clearance for ablation of the full range of esophageal disease, including cancer of the esophagus and Barrett's esophagus with low and/or high grade dysplasia. The truFreeze system is currently being utilized in a prospective, open label, non-controlled single arm, multi-center study: "truFreeze palliative esophageal cancer study". The primary bjective is to study the effects of the truFreeze Spray Cryotherapy System in a population of subjects who have been diagnosed with persistent local esophageal cancer and who are not surgical candidates or have completed or declined systemic therapy. For more information, visit www.clinicaltrials.gov About Esophageal Cancer About CSA Medical To learn more about our technology, visit www.csamedical.com. truFreeze® is a registered trademark of CSA Medical, Inc. 1. American Cancer Society data For further information contact: View original content with multimedia:http://www.prnewswire.com/news-releases/csa-medical-supports-esophageal-cancer-awareness-month-300622684.html SOURCE CSA Medical |